CryoPort, Inc. $CYRX Holdings Lowered by Readystate Asset Management LP

Readystate Asset Management LP decreased its stake in CryoPort, Inc. (NASDAQ:CYRX) by 20.5% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 228,822 shares of the company’s stock after selling 58,851 shares during the quarter. Readystate Asset Management LP owned 0.45% of CryoPort worth $1,895,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Basepoint Wealth LLC acquired a new stake in CryoPort during the 4th quarter worth about $34,000. Tower Research Capital LLC TRC boosted its holdings in shares of CryoPort by 300.1% in the second quarter. Tower Research Capital LLC TRC now owns 5,833 shares of the company’s stock worth $44,000 after buying an additional 4,375 shares during the period. Creative Planning acquired a new position in shares of CryoPort in the second quarter worth about $96,000. Quadrature Capital Ltd purchased a new position in shares of CryoPort in the fourth quarter worth approximately $97,000. Finally, State of Wyoming increased its position in shares of CryoPort by 30.2% in the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after acquiring an additional 3,301 shares in the last quarter. Hedge funds and other institutional investors own 92.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on CYRX shares. Jefferies Financial Group set a $13.50 price target on shares of CryoPort in a research report on Monday, June 8th. Weiss Ratings upgraded shares of CryoPort from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Wednesday, May 6th. Wall Street Zen raised shares of CryoPort from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. KeyCorp increased their target price on CryoPort from $15.00 to $17.00 and gave the company an “overweight” rating in a report on Wednesday, May 20th. Finally, Needham & Company LLC raised their target price on CryoPort from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, CryoPort presently has a consensus rating of “Moderate Buy” and an average price target of $16.38.

CryoPort Stock Up 0.1%

CYRX stock opened at $15.17 on Wednesday. The company has a 50 day moving average of $15.37 and a two-hundred day moving average of $11.68. The company has a market cap of $764.57 million, a price-to-earnings ratio of 11.24 and a beta of 1.88. CryoPort, Inc. has a 12-month low of $6.69 and a 12-month high of $16.89.

CryoPort (NASDAQ:CYRX) last posted its quarterly earnings results on Monday, May 4th. The company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.03). CryoPort had a net margin of 41.57% and a negative return on equity of 7.92%. The company had revenue of $47.80 million for the quarter, compared to analysts’ expectations of $44.86 million. On average, research analysts anticipate that CryoPort, Inc. will post -0.85 EPS for the current year.

Insider Activity at CryoPort

In other CryoPort news, insider Edward J. Zecchini sold 33,600 shares of the business’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $14.47, for a total value of $486,192.00. Following the transaction, the insider owned 109,719 shares in the company, valued at $1,587,633.93. The trade was a 23.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Ramkumar Mandalam sold 23,214 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $15.44, for a total value of $358,424.16. Following the completion of the transaction, the director directly owned 67,894 shares in the company, valued at approximately $1,048,283.36. The trade was a 25.48% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 227,641 shares of company stock valued at $3,622,515. Insiders own 9.50% of the company’s stock.

CryoPort Profile

CryoPort, Inc (NASDAQ: CYRX) is a global provider of temperature-controlled logistics solutions for the life sciences industry. The company specializes in cryogenic shipping for critical biological materials, supporting the development, clinical testing and commercialization of cell and gene therapies, biologics, vaccines and reproductive medicine. By offering end-to-end supply chain management, CryoPort helps ensure the integrity and viability of temperature-sensitive products from point of origin to destination.

CryoPort’s product portfolio includes proprietary cryogenic dry shippers, advanced active and passive thermal packaging, and real-time data monitoring platforms.